{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:44:58Z","timestamp":1794638698604,"version":"4.9.1"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.eplepsyres.2024.107317","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T01:08:01Z","timestamp":1707181681000},"page":"107317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Effect of intracerebroventricular administration of alglucosidase alfa in two mouse models of Lafora disease: Relevance for clinical practice"],"prefix":"10.1016","volume":"200","author":[{"given":"Luis","family":"Zafra-Puerta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Colpaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"Iglesias-Cabeza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Burgos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"S\u00e1nchez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Gentry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina P.","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Serratosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2024.107317_bib1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.5357\/koubyou.60.264","article-title":"Production of monoclonal antibody that recognizes glycogen and its application for immunohistochemistry. Kokubyo Gakkai zasshi","volume":"60","author":"Baba","year":"1993","journal-title":"J. Stomatol. Soc. Jpn."},{"key":"10.1016\/j.eplepsyres.2024.107317_bib2","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.cmet.2019.07.002","article-title":"Targeting pathogenic lafora bodies in Lafora disease using an antibody-enzyme fusion","volume":"30","author":"Brewer","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.eplepsyres.2024.107317_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2020.116260","article-title":"Polyglucosan body structure in Lafora disease","volume":"240","author":"Brewer","year":"2020","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.eplepsyres.2024.107317_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2023.106119","article-title":"Epm2a(R240X) knock-in mice present earlier cognitive decline and more epileptic activity than Epm2a(-\/-) mice.","volume":"181","author":"Burgos","year":"2023","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.eplepsyres.2024.107317_bib5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/ng1238","article-title":"Mutations in NHLRC1 cause progressive myoclonus epilepsy","volume":"35","author":"Chan","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.eplepsyres.2024.107317_bib6","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/hmg\/ddu024","article-title":"Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease","volume":"23","author":"Duran","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.eplepsyres.2024.107317_bib7","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1093\/oxfordjournals.hmg.a018916","article-title":"Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes","volume":"9","author":"Ganesh","year":"2000","journal-title":"Hum. Mol. Genet"},{"key":"10.1016\/j.eplepsyres.2024.107317_bib8","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/hmg\/11.11.1251","article-title":"Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice","volume":"11","author":"Ganesh","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.eplepsyres.2024.107317_bib9","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1073\/pnas.0503285102","article-title":"Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin","volume":"102","author":"Gentry","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.eplepsyres.2024.107317_bib10","doi-asserted-by":"crossref","first-page":"7117","DOI":"10.1074\/jbc.R117.803064","article-title":"Lafora disease offers a unique window into neuronal glycogen metabolism","volume":"293","author":"Gentry","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.eplepsyres.2024.107317_bib11","first-page":"928","article-title":"Pompe disease: from basic science to therapy","volume":"15","author":"Kohler","year":"2018","journal-title":"Neurother. J. Am. Soc. Exp. Neurother."},{"key":"10.1016\/j.eplepsyres.2024.107317_bib12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF01989438","article-title":"\u00dcber das Vorkommen amyloider K\u00f6rperchen im Innern der Ganglienzellen. Virchows","volume":"205","author":"Lafora","year":"1911","journal-title":"Arch. Pathol. Anat. Physiol. Klin. Med."},{"key":"10.1016\/j.eplepsyres.2024.107317_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02863929","article-title":"Beitrag zur Histopathologie der myoklonischen Epilepsie","volume":"6","author":"Lafora","year":"1911","journal-title":"Z. Gesamt Neurol. Psychiatr."},{"key":"10.1016\/j.eplepsyres.2024.107317_bib14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/2470","article-title":"Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy","volume":"20","author":"Minassian","year":"1998","journal-title":"Nat. Genet."},{"key":"10.1016\/j.eplepsyres.2024.107317_bib15","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/hmg\/4.9.1657","article-title":"The gene for progressive myoclonus epilepsy of the Lafora type maps to chromosome 6q","volume":"4","author":"Serratosa","year":"1995","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.eplepsyres.2024.107317_bib16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/hmg\/8.2.345","article-title":"A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2)","volume":"8","author":"Serratosa","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.eplepsyres.2024.107317_bib17","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/nn1998","article-title":"Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy","volume":"10","author":"Vilchez","year":"2007","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.eplepsyres.2024.107317_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1001\/archneur.1968.00480010033002","article-title":"Studies in myoclonus epilepsy (Lafora body form). I. Isolation and preliminary characterization of Lafora bodies in two cases","volume":"19","author":"Yokoi","year":"1968","journal-title":"Arch. Neurol."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121124000329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121124000329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T03:17:21Z","timestamp":1736219841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121124000329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":18,"alternative-id":["S0920121124000329"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2024.107317","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of intracerebroventricular administration of alglucosidase alfa in two mouse models of Lafora disease: Relevance for clinical practice","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2024.107317","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107317"}}